ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

ClinicalTrials.gov ID: NCT02460224

Public ClinicalTrials.gov record NCT02460224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies

Study identification

NCT ID
NCT02460224
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
490 participants

Conditions and interventions

Interventions

  • LAG525 Drug
  • PDR001 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 16, 2015
Primary completion
Dec 30, 2020
Completion
Dec 30, 2020
Last update posted
Feb 9, 2022

2015 – 2020

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
5
Facility City State ZIP Site status
Columbia University Medical Center SC LAG X2101C New York New York 10032
Memorial Sloan Kettering Cancer Center SC New York New York 10065
Duke Clinical Research Institute SC Durham North Carolina 27704
University of Texas MD Anderson Cancer Center Houston Texas 77030
Cancer Therapy and Research Center UT Health Science Center CTRC 2 San Antonio Texas 78229
Huntsman Cancer Institute Huntsman Cancer Institute Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02460224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2022 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02460224 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →